Genentech sees the light for Lucentis at end of Phase III RVO trials
This article was originally published in Scrip
Executive Summary
Genentech's VEGF-inhibitor Lucentis (ranibizumab) improved vision in patients suffering from retinal vein occlusion (RVO), show results from two Phase III trials. The US company plans to file the drug for this indication in the US in the first quarter of 2010.